In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
Continued growth in the giant and growing market for heart failure treatments looks assured for British pharma major AstraZeneca, with more positive data for its glucose lowering blockbuster Farxiga (dapagliflozin). 8 November 2022
Pharmaceutical
German life sciences giant Bayer has reported an increase in sales across the group in the third quarter 2022, up 5.7% to 11.3 billion euros ($11.3 billion). 8 November 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Biotechnology
US biotech Mirum Pharmaceuticals saw its shares rise 3% to $23.69 yesterday, when it presented new data from Livmarli (maralixibat) oral solution studies at The Liver Meeting of the American Association for the Study of Liver Diseases. 8 November 2022
Biotechnology
Shares in Nicox tumbled last week as investors digested the mixed results from its Mont Blanc Phase III trial evaluating NCX 470 in open angle glaucoma or ocular hypertension. 7 November 2022
Biotechnology
UK pharma major GSK’s shares were down 4.3% at 1,383.60 pence by early afternoon today, as it announced disappointing Phase III results with its Blenrep (belantamab mafodotin). 7 November 2022
Biotechnology
Shares of Germany-based BioNTech were down 6.8% at $147.48 in pre-market New York trading as it reported third-quarter 2022 financial results, showing that sales and profits were almost half those of the comparable 2021 quarter figures. 7 November 2022
Biotechnology
Shares in Sensorion, a French biotech that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, were trading 17% higher on Monday afternoon. 7 November 2022
Generics
Sandoz, the soon to be divested generic and biosimilar medicines business of Swiss pharm giant Novartis, today announced an additional investment of 50 million euros ($49.5 million) to support increased European manufacturing capacity for finished dosage form (FDF) penicillins, the leading class of antibiotics worldwide. 7 November 2022
Generics
New York Attorney General Letitia James last Friday marked a major milestone in her fight against the opioid crisis in New York state, when she announced that her office has secured up to $523 million from the US subsidiary and affiliates of Israeli generics giant Teva Pharmaceutical Industries for their role in fueling the opioid crisis. 7 November 2022
Biotechnology
Biopharmaceutical firms in China are focusing on the development of new COVID-19 treatments, designed to tackle new Omicron variants. 7 November 2022
Pharmaceutical
In what should be a wake-up call for the European pharma sector, a new report published today by Charles River Associates for the European Federation of Pharmaceutical Industries and Associations (EFPIA) paints a challenging picture of falling competitiveness in Europe, with the global share of pharmaceutical R&D investment, clinical trials and manufacturing output all decreasing. 7 November 2022
Biotechnology
France’s GenSight Biologics saw its shares close up 8.7% at 3.71 euros on Friday, after it announced it has entered into a 35 million-euro ($34.6 million) credit facility agreement with the European Investment Bank (EIB), supported by the European Fund for Strategic Investment (EFSI). 7 November 2022
Pharmaceutical
Japanese drug major Eisai today announced that it has entered into an agreement to divest its rights for muscle relaxant Myonal (eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate) in Asia to a subsidiary of Switzerland-based DKSH Holding Ltd. 7 November 2022
article
The pace of innovation and digital transformation is increasing in the life science industry, particularly regarding regulatory compliance. As a result of the pandemic, when new age technologies were used to rapidly develop COVID-19 vaccines, treatments and tests, the use of automation and artificial intelligence to also optimize pharmacovigilance (PV) and regulatory compliance operations is on the rise. 6 November 2022
Biotechnology
Featured research news last week included US pharma major Bristol Myers Squibb releasing top-line results from a Phase III study suggesting its Reblozyl can address a wider myelodysplastic syndrome patient group. Actinium Pharmaceuticals reported positive top-line Phase III results for it acute myeloid leukemia (AML) candidate Iomab-B. Also, US pharma giant Pfizer last Tuesday presented strong data for its RSVpreF respiratory syncytial virus (RSV) vaccine program. On the deal-making front, US MRNA technology company Arcturus Therapeutics hit the jackpot last week, inking a potentially hugely lucrative deal with Australian biotech CSL Limited, to access the firm’s late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology. 6 November 2022
Pharmaceutical
US drug developer Ionis Pharmaceuticals saw its shares close down 8.5% at $40.98 on Friday, after it revealed that its licensing partner, Germany’s Bayer, had pulled out of a deal for the development of fesomersen. 5 November 2022
Biotechnology
The US Food and Drug Administration (FDA) on Friday updated the Health Care Provider Fact Sheet for bebtelovimab with specific information regarding expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2. This information shows that bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. 5 November 2022
Biotechnology
An Expert View from RJ Tesi, co-founder and chief executive of INmune Bio. 4 November 2022
Biotechnology
The European Commission (EC) has approved Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. 4 November 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze